Wall Street Zen Upgrades Sangamo Therapeutics (NASDAQ:SGMO) to “Hold”

Sangamo Therapeutics (NASDAQ:SGMO) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Other equities research analysts also recently issued research reports about the stock. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Sangamo Therapeutics in a research report on Tuesday, June 24th. Barclays cut their price target on shares of Sangamo Therapeutics from $9.00 to $5.00 and set an “overweight” rating on the stock in a report on Wednesday, May 14th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $4.50.

Sangamo Therapeutics Stock Performance

Sangamo Therapeutics stock opened at $0.58 on Friday. The company has a 50 day moving average price of $0.52 and a 200 day moving average price of $0.71. Sangamo Therapeutics has a 52 week low of $0.41 and a 52 week high of $3.18. The firm has a market capitalization of $174.99 million, a price-to-earnings ratio of -2.00 and a beta of 1.18.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). Sangamo Therapeutics had a negative return on equity of 293.05% and a negative net margin of 77.48%. The firm had revenue of $18.31 million during the quarter, compared to analyst estimates of $31.68 million. Equities analysts forecast that Sangamo Therapeutics will post -0.46 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. grew its stake in Sangamo Therapeutics by 679.5% in the 4th quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 21,793 shares during the last quarter. Captrust Financial Advisors acquired a new stake in Sangamo Therapeutics in the 4th quarter worth $30,000. LPL Financial LLC grew its position in Sangamo Therapeutics by 113.5% in the 4th quarter. LPL Financial LLC now owns 31,031 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 16,498 shares during the last quarter. Lazard Asset Management LLC acquired a new stake in Sangamo Therapeutics in the 4th quarter worth $47,000. Finally, R Squared Ltd acquired a new stake in Sangamo Therapeutics in the 2nd quarter worth $28,000. 56.93% of the stock is currently owned by institutional investors and hedge funds.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.